Literature DB >> 10908891

PET shows that striatal dopamine D1 and D2 receptors are differentially affected in AD.

N Kemppainen1, H Ruottinen, K Nâgren, J O Rinne.   

Abstract

OBJECTIVE: To study dopamine D1 and D2 receptors in the putamen and the caudate nucleus in patients with AD and age-matched healthy controls by means of PET.
METHODS: A dopamine D1 receptor antagonist ([11C]NNC 756) and a D2 receptor antagonist ([11C]raclopride) were used as ligands. The uptake of these ligands was calculated as a distribution volume ratio of the putamen and the caudate nucleus to the cerebellum.
RESULTS: The mean [11C]NNC 756 uptake in AD was reduced by 14% from the mean control value both in the putamen (p = 0.004) and the caudate nucleus (p = 0.009). There was no significant reduction in the mean [11C]raclopride uptake in either the putamen or the caudate nucleus in AD. There was no correlation between [11C]NNC 756 or [11C]raclopride uptake and Mini-Mental State Examination or motor Unified PD Rating Scale scores in patients with AD.
CONCLUSIONS: There are changes in striatal D1 but not in D2 receptors in AD.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10908891     DOI: 10.1212/wnl.55.2.205

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  14 in total

1.  3D maps localize caudate nucleus atrophy in 400 Alzheimer's disease, mild cognitive impairment, and healthy elderly subjects.

Authors:  S K Madsen; A J Ho; X Hua; P S Saharan; A W Toga; C R Jack; M W Weiner; P M Thompson
Journal:  Neurobiol Aging       Date:  2010-06-11       Impact factor: 4.673

Review 2.  Molecular Signaling Mechanisms of Natural and Synthetic Retinoids for Inhibition of Pathogenesis in Alzheimer's Disease.

Authors:  Mrinmay Chakrabarti; Alexander J McDonald; J Will Reed; Melissa A Moss; Bhaskar C Das; Swapan K Ray
Journal:  J Alzheimers Dis       Date:  2016       Impact factor: 4.472

Review 3.  Imaging of the dopaminergic system in differential diagnosis of dementia.

Authors:  Klaus Tatsch
Journal:  Eur J Nucl Med Mol Imaging       Date:  2008-03       Impact factor: 9.236

Review 4.  The ART of loss: Abeta imaging in the evaluation of Alzheimer's disease and other dementias.

Authors:  Victor L Villemagne; Michelle T Fodero-Tavoletti; Kerryn E Pike; Roberto Cappai; Colin L Masters; Christopher C Rowe
Journal:  Mol Neurobiol       Date:  2008-08-09       Impact factor: 5.590

Review 5.  Neurotransmitter receptors and cognitive dysfunction in Alzheimer's disease and Parkinson's disease.

Authors:  Yunqi Xu; Junqiang Yan; Peng Zhou; Jiejie Li; Huimin Gao; Ying Xia; Qing Wang
Journal:  Prog Neurobiol       Date:  2012-02-25       Impact factor: 11.685

6.  Periodic leg movements in sleep in elderly patients with Parkinsonism and Alzheimer's disease.

Authors:  D L Bliwise; L M Trotti; J A Yesavage; D B Rye
Journal:  Eur J Neurol       Date:  2012-02-16       Impact factor: 6.089

7.  New therapeutic strategies targeting D1-type dopamine receptors for neuropsychiatric disease.

Authors:  Young-Cho Kim; Stephanie L Alberico; Eric Emmons; Nandakumar S Narayanan
Journal:  Front Biol (Beijing)       Date:  2015-05-13

Review 8.  The use of PET in Alzheimer disease.

Authors:  Agneta Nordberg; Juha O Rinne; Ahmadul Kadir; Bengt Långström
Journal:  Nat Rev Neurol       Date:  2010-02       Impact factor: 42.937

9.  Differential contributions of dopaminergic D1- and D2-like receptors to cognitive function in rhesus monkeys.

Authors:  Stefani N Von Huben; Sophia A Davis; Christopher C Lay; Simon N Katner; Rebecca D Crean; Michael A Taffe
Journal:  Psychopharmacology (Berl)       Date:  2006-03-15       Impact factor: 4.530

Review 10.  Radiopharmaceuticals for positron emission tomography investigations of Alzheimer's disease.

Authors:  Kjell Någren; Christer Halldin; Juha O Rinne
Journal:  Eur J Nucl Med Mol Imaging       Date:  2009-12-22       Impact factor: 9.236

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.